+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiovascular Drugs Market Research Reports

From
From
From
Dyslipidemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Dyslipidemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Anti-hypertension - Epidemiology Forecast to 2032 - Product Thumbnail Image

Anti-hypertension - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Atrial Fibrillation - Epidemiology Forecast to 2032 - Product Thumbnail Image

Atrial Fibrillation - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Acute Heart failure (AHF) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Acute Heart failure (AHF) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Critical Limb Ischemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Critical Limb Ischemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Vasculitis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Vasculitis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Varicose Veins - Epidemiology Forecast to 2032 - Product Thumbnail Image

Varicose Veins - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Familial Hypercholesterolemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Familial Hypercholesterolemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Hypertriglyceridemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hypertriglyceridemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Acute Coronary Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Acute Coronary Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Pulmonary Embolism - Epidemiology Forecast to 2032 - Product Thumbnail Image

Pulmonary Embolism - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Hypercholesterolemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hypercholesterolemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Cardiotoxicity - Epidemiology Forecast to 2032 - Product Thumbnail Image

Cardiotoxicity - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Danon Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Danon Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Abdominal Aortic Aneurysm - Epidemiology Forecast to 2032 - Product Thumbnail Image

Abdominal Aortic Aneurysm - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Angioedema - Epidemiology Forecast to 2032 - Product Thumbnail Image

Angioedema - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more